Antiphospholipid antibodies in patients with calcific aortic valve stenosis
Abstract Objectives The antiphospholipid syndrome is defined by antiphospholipid antibodies (aPL) together with arterial and/or venous thromboembolism and/or obstetric morbidities. aPL are overrepresented in SLE and acute myocardial infarction, but it is unknown whether aPL are associated with calci...
Saved in:
| Published in | Rheumatology (Oxford, England) Vol. 62; no. 3; pp. 1187 - 1196 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Oxford University Press
01.03.2023
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1462-0324 1462-0332 1462-0332 |
| DOI | 10.1093/rheumatology/keac466 |
Cover
| Abstract | Abstract
Objectives
The antiphospholipid syndrome is defined by antiphospholipid antibodies (aPL) together with arterial and/or venous thromboembolism and/or obstetric morbidities. aPL are overrepresented in SLE and acute myocardial infarction, but it is unknown whether aPL are associated with calcific aortic valve stenosis (CAVS) in the general population. The prevalence of aPL and other SLE-associated autoantibodies and their impact on aortic valve transcriptomics were therefore determined.
Methods
A total of 233 tricuspid CAVS cases (median age 74, 69% male) and an age- and sex-matched control population were included. aPL were measured as anti-cardiolipin and anti-β2Glycoprotein-I of IgG/M/A isotypes. Resilient, thickened and calcified aortic valve (AV) tissue derived from five aPL positive and five matched aPL negative CAVS patients undergoing surgical aortic valve replacement were analysed by microarrays.
Results
The prevalence of positivity for any aPL (IgG/M/A) in patients with CAVS was 6.4% (95% CI 3.6% – 10.4%: n = 233). aPL IgG was significantly more prevalent in CAVS cases vs controls (4.6% vs 0.6%, P = 0.04). AV tissue from aPL IgG/IgM-positive patients was negatively enriched in pathways related to interferon signalling. One hundred differentially expressed genes could predict local AV CAVS progression with supervised machine learning algorithms.
Conclusions
aPL IgG was more common in CAVS patients compared with matched controls and aPL positivity was associated with altered AV transcriptomics related to local disease progression and interferon pathways. Further studies should aim to establish aPL as a possible risk marker and/or causal factor for CAVS and could offer new precision therapeutic targets. |
|---|---|
| AbstractList | The antiphospholipid syndrome is defined by antiphospholipid antibodies (aPL) together with arterial and/or venous thromboembolism and/or obstetric morbidities. aPL are overrepresented in SLE and acute myocardial infarction, but it is unknown whether aPL are associated with calcific aortic valve stenosis (CAVS) in the general population. The prevalence of aPL and other SLE-associated autoantibodies and their impact on aortic valve transcriptomics were therefore determined.
A total of 233 tricuspid CAVS cases (median age 74, 69% male) and an age- and sex-matched control population were included. aPL were measured as anti-cardiolipin and anti-β2Glycoprotein-I of IgG/M/A isotypes. Resilient, thickened and calcified aortic valve (AV) tissue derived from five aPL positive and five matched aPL negative CAVS patients undergoing surgical aortic valve replacement were analysed by microarrays.
The prevalence of positivity for any aPL (IgG/M/A) in patients with CAVS was 6.4% (95% CI 3.6% - 10.4%: n = 233). aPL IgG was significantly more prevalent in CAVS cases vs controls (4.6% vs 0.6%, P = 0.04). AV tissue from aPL IgG/IgM-positive patients was negatively enriched in pathways related to interferon signalling. One hundred differentially expressed genes could predict local AV CAVS progression with supervised machine learning algorithms.
aPL IgG was more common in CAVS patients compared with matched controls and aPL positivity was associated with altered AV transcriptomics related to local disease progression and interferon pathways. Further studies should aim to establish aPL as a possible risk marker and/or causal factor for CAVS and could offer new precision therapeutic targets. Abstract Objectives The antiphospholipid syndrome is defined by antiphospholipid antibodies (aPL) together with arterial and/or venous thromboembolism and/or obstetric morbidities. aPL are overrepresented in SLE and acute myocardial infarction, but it is unknown whether aPL are associated with calcific aortic valve stenosis (CAVS) in the general population. The prevalence of aPL and other SLE-associated autoantibodies and their impact on aortic valve transcriptomics were therefore determined. Methods A total of 233 tricuspid CAVS cases (median age 74, 69% male) and an age- and sex-matched control population were included. aPL were measured as anti-cardiolipin and anti-β2Glycoprotein-I of IgG/M/A isotypes. Resilient, thickened and calcified aortic valve (AV) tissue derived from five aPL positive and five matched aPL negative CAVS patients undergoing surgical aortic valve replacement were analysed by microarrays. Results The prevalence of positivity for any aPL (IgG/M/A) in patients with CAVS was 6.4% (95% CI 3.6% – 10.4%: n = 233). aPL IgG was significantly more prevalent in CAVS cases vs controls (4.6% vs 0.6%, P = 0.04). AV tissue from aPL IgG/IgM-positive patients was negatively enriched in pathways related to interferon signalling. One hundred differentially expressed genes could predict local AV CAVS progression with supervised machine learning algorithms. Conclusions aPL IgG was more common in CAVS patients compared with matched controls and aPL positivity was associated with altered AV transcriptomics related to local disease progression and interferon pathways. Further studies should aim to establish aPL as a possible risk marker and/or causal factor for CAVS and could offer new precision therapeutic targets. The antiphospholipid syndrome is defined by antiphospholipid antibodies (aPL) together with arterial and/or venous thromboembolism and/or obstetric morbidities. aPL are overrepresented in SLE and acute myocardial infarction, but it is unknown whether aPL are associated with calcific aortic valve stenosis (CAVS) in the general population. The prevalence of aPL and other SLE-associated autoantibodies and their impact on aortic valve transcriptomics were therefore determined.OBJECTIVESThe antiphospholipid syndrome is defined by antiphospholipid antibodies (aPL) together with arterial and/or venous thromboembolism and/or obstetric morbidities. aPL are overrepresented in SLE and acute myocardial infarction, but it is unknown whether aPL are associated with calcific aortic valve stenosis (CAVS) in the general population. The prevalence of aPL and other SLE-associated autoantibodies and their impact on aortic valve transcriptomics were therefore determined.A total of 233 tricuspid CAVS cases (median age 74, 69% male) and an age- and sex-matched control population were included. aPL were measured as anti-cardiolipin and anti-β2Glycoprotein-I of IgG/M/A isotypes. Resilient, thickened and calcified aortic valve (AV) tissue derived from five aPL positive and five matched aPL negative CAVS patients undergoing surgical aortic valve replacement were analysed by microarrays.METHODSA total of 233 tricuspid CAVS cases (median age 74, 69% male) and an age- and sex-matched control population were included. aPL were measured as anti-cardiolipin and anti-β2Glycoprotein-I of IgG/M/A isotypes. Resilient, thickened and calcified aortic valve (AV) tissue derived from five aPL positive and five matched aPL negative CAVS patients undergoing surgical aortic valve replacement were analysed by microarrays.The prevalence of positivity for any aPL (IgG/M/A) in patients with CAVS was 6.4% (95% CI 3.6% - 10.4%: n = 233). aPL IgG was significantly more prevalent in CAVS cases vs controls (4.6% vs 0.6%, P = 0.04). AV tissue from aPL IgG/IgM-positive patients was negatively enriched in pathways related to interferon signalling. One hundred differentially expressed genes could predict local AV CAVS progression with supervised machine learning algorithms.RESULTSThe prevalence of positivity for any aPL (IgG/M/A) in patients with CAVS was 6.4% (95% CI 3.6% - 10.4%: n = 233). aPL IgG was significantly more prevalent in CAVS cases vs controls (4.6% vs 0.6%, P = 0.04). AV tissue from aPL IgG/IgM-positive patients was negatively enriched in pathways related to interferon signalling. One hundred differentially expressed genes could predict local AV CAVS progression with supervised machine learning algorithms.aPL IgG was more common in CAVS patients compared with matched controls and aPL positivity was associated with altered AV transcriptomics related to local disease progression and interferon pathways. Further studies should aim to establish aPL as a possible risk marker and/or causal factor for CAVS and could offer new precision therapeutic targets.CONCLUSIONSaPL IgG was more common in CAVS patients compared with matched controls and aPL positivity was associated with altered AV transcriptomics related to local disease progression and interferon pathways. Further studies should aim to establish aPL as a possible risk marker and/or causal factor for CAVS and could offer new precision therapeutic targets. |
| Author | Plunde, Oscar Franco-Cereceda, Anders Svenungsson, Elisabet Bäck, Magnus Ferrannini, Giulia |
| Author_xml | – sequence: 1 givenname: Oscar orcidid: 0000-0003-1343-2198 surname: Plunde fullname: Plunde, Oscar email: oscar.persson@ki.se – sequence: 2 givenname: Elisabet orcidid: 0000-0003-3396-3244 surname: Svenungsson fullname: Svenungsson, Elisabet – sequence: 3 givenname: Giulia surname: Ferrannini fullname: Ferrannini, Giulia – sequence: 4 givenname: Anders surname: Franco-Cereceda fullname: Franco-Cereceda, Anders – sequence: 5 givenname: Magnus surname: Bäck fullname: Bäck, Magnus |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35961031$$D View this record in MEDLINE/PubMed http://kipublications.ki.se/Default.aspx?queryparsed=id:150551168$$DView record from Swedish Publication Index |
| BookMark | eNqNUctu2zAQJIoUzaP9g6LQsRfVfEik1EOBIOgLCdBLeiZW9CpmQ5OqSNnw35eGHCPpJTkQu9idmeXOnpMTHzwS8p7RT4y2YjGucFpDCi7c7Rb3CKaS8hU5Y5XkJRWCnxxzXp2S8xj_UEprJpo35FTUrWRUsDNyfemTHVYh5ufsYJcF5EIXlhZjYX0xQLLoUyy2Nq0KA87Y3poCwphy2IDbYBET-hBtfEte9-AivjvEC_L729fbqx_lza_vP68ub0pTNTKViAqUWLaSt32HrKeM910PjZB1q1re1lxR4Fx2UnaqVg1jjQIQKCgKyXshLkg9605-gN0WnNPDaNcw7jSjem-OfmyOPpiTeeXMi1scpu5ICmD1oXSfM9RVzeqqzvgvMz531rg02YcR3BPa0463K30XNrptlWJMZYGPB4Ex_J0wJr220aBz4DFMUedFOWsqzvfQD49nHYc8XCoDqhlgxhDjiP1Ld_78H83YlG8a9j-27jnyYiaHaXjZuH9aE9bS |
| CitedBy_id | crossref_primary_10_1038_s41584_024_01110_y crossref_primary_10_1016_j_clim_2024_109906 crossref_primary_10_1016_j_clim_2023_109790 crossref_primary_10_1093_ehjopen_oeac084 |
| Cites_doi | 10.1016/j.jacc.2017.02.058 10.1161/CIRCRESAHA.108.192765 10.1016/j.jacc.2019.01.070 10.1161/01.CIR.90.2.844 10.1136/heartjnl-2020-318733 10.1038/nrdp.2017.103 10.1093/eurheartj/ehy696 10.1111/j.1538-7836.2006.01753.x 10.1172/JCI39828 10.1016/S0735-1097(96)00563-3 10.1161/CIRCULATIONAHA.111.028522 10.1016/j.atherosclerosis.2007.05.030 10.1055/s-0039-1685453 10.1038/nrdp.2016.6 10.1016/j.jacbts.2021.02.005 10.1111/jth.13379 10.1016/j.jacbts.2021.07.008 10.1016/j.ijcard.2019.10.042 10.1056/NEJMoa1109034 10.1161/CIRCGEN.119.002710 10.1111/joim.13409 10.1056/NEJMra1313875 10.1136/ard.2009.115535 10.1007/s00125-019-05019-0 10.1124/jpet.110.177915 10.7326/M18-2130 10.1111/jth.15585 10.1515/cclm-2013-0741 10.3389/fimmu.2019.00487 10.1161/CIRCULATIONAHA.121.054182 10.1186/s13075-019-1878-y 10.1371/journal.pone.0156407 10.1161/CIRCRESAHA.110.234146 10.1101/gr.1239303 10.1016/j.celrep.2018.09.002 10.1046/j.1365-2249.1997.d01-948.x 10.1016/j.jacc.2015.07.020 10.1016/S0092-8674(01)00628-6 10.1161/CIRCGENETICS.110.948935 10.3389/fcvm.2019.00018 10.1161/ATVBAHA.118.311504 10.1056/NEJMoa073003 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology. 2022 The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology. |
| Copyright_xml | – notice: The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology. 2022 – notice: The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology. |
| DBID | TOX AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM ADTPV AOWAS D8T ZZAVC ADTOC UNPAY |
| DOI | 10.1093/rheumatology/keac466 |
| DatabaseName | Oxford Journals Open Access Collection CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) SwePub SwePub Articles SWEPUB Freely available online SwePub Articles full text Unpaywall for CDI: Periodical Content Unpaywall |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: TOX name: Oxford Journals Open Access Collection url: https://academic.oup.com/journals/ sourceTypes: Publisher – sequence: 4 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1462-0332 |
| EndPage | 1196 |
| ExternalDocumentID | 10.1093/rheumatology/keac466 oai_swepub_ki_se_451545 PMC9977117 35961031 10_1093_rheumatology_keac466 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: ; grantid: 2019–01486; 2018–02535 – fundername: ; – fundername: ; grantid: 20170365; 20170038 – fundername: ; grantid: 20180571; 20170257 – fundername: ; grantid: SLS-713911 |
| GroupedDBID | --- -E4 .2P .GJ .I3 .XZ .ZR 08P 0R~ 18M 1TH 29P 2WC 354 3O- 4.4 48X 53G 5RE 5VS 5WA 5WD 70D AABZA AACZT AAGKA AAJKP AAJQQ AAMDB AAMVS AAOGV AAPGJ AAPNW AAPQZ AAPXW AARHZ AAUAY AAUQX AAVAP AAWDT AAWTL ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABKDP ABLJU ABNGD ABNHQ ABNKS ABOCM ABPTD ABQLI ABQNK ABQTQ ABVGC ABXVV ABZBJ ACFRR ACGFO ACGFS ACPRK ACUFI ACUKT ACUTJ ACUTO ACYHN ADBBV ADEYI ADEZT ADGZP ADHKW ADHZD ADIPN ADMTO ADNBA ADOCK ADQBN ADRTK ADVEK ADYVW ADZXQ AEGPL AEGXH AEHUL AEJOX AEKSI AEMDU AEMQT AENEX AENZO AEPUE AETBJ AEWNT AFFNX AFFZL AFIYH AFOFC AFXAL AGINJ AGKEF AGSYK AGUTN AHMBA AHMMS AHXPO AIAGR AIJHB AJEEA AJNCP AKWXX ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT APWMN AQDSO ATGXG ATTQO AXUDD AZFZN BAWUL BAYMD BCRHZ BEYMZ BHONS BTRTY BVRKM C45 CAG CDBKE COF CS3 CZ4 DAKXR DIK DILTD DU5 D~K E3Z EBD EBS EE~ EIHJH EJD EMOBN ENERS F5P F9B FECEO FEDTE FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HVGLF HW0 HZ~ IOX J21 JXSIZ KAQDR KBUDW KOP KQ8 KSI KSN L7B M-Z M49 MHKGH N9A NGC NOMLY NOYVH NTWIH NU- NVLIB O0~ O9- OAUYM OAWHX OBH OCZFY ODMLO OHH OJQWA OJZSN OPAEJ OVD OWPYF O~Y P2P PAFKI PB- PEELM PQQKQ Q1. Q5Y R44 RD5 RIG RNI ROL ROX RUSNO RW1 RXO RZF RZO SV3 TCURE TEORI TJX TMA TOX TR2 VVN W8F WOQ X7H YAYTL YKOAZ YXANX ZGI ZKX ZY1 ~91 AAYXX AHGBF AJBYB CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM ADTPV AGQPQ AOWAS D8T ZZAVC ADTOC UNPAY |
| ID | FETCH-LOGICAL-c486t-ee7a73d9629fbe1f012fbfa8365979295270a226b66b75781187aa3e30e362f33 |
| IEDL.DBID | UNPAY |
| ISSN | 1462-0324 1462-0332 |
| IngestDate | Sun Oct 26 04:08:08 EDT 2025 Mon Oct 20 03:22:57 EDT 2025 Tue Sep 30 17:16:45 EDT 2025 Thu Oct 02 10:07:51 EDT 2025 Thu Apr 03 06:57:20 EDT 2025 Wed Oct 01 04:43:26 EDT 2025 Thu Apr 24 23:06:04 EDT 2025 Wed Apr 02 07:05:35 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | antiphospholipid syndrome transcriptomics aPL calcific aortic valve stenosis SLE heart valve disease |
| Language | English |
| License | This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com https://creativecommons.org/licenses/by-nc/4.0 The Author(s) 2022. Published by Oxford University Press on behalf of the British Society for Rheumatology. cc-by-nc |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c486t-ee7a73d9629fbe1f012fbfa8365979295270a226b66b75781187aa3e30e362f33 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Anders Franco-Cereceda and Magnus Bäck contributed equally to this study. |
| ORCID | 0000-0003-3396-3244 0000-0003-1343-2198 |
| OpenAccessLink | https://proxy.k.utb.cz/login?url=https://academic.oup.com/rheumatology/advance-article-pdf/doi/10.1093/rheumatology/keac466/45600133/keac466.pdf |
| PMID | 35961031 |
| PQID | 2702184227 |
| PQPubID | 23479 |
| PageCount | 10 |
| ParticipantIDs | unpaywall_primary_10_1093_rheumatology_keac466 swepub_primary_oai_swepub_ki_se_451545 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9977117 proquest_miscellaneous_2702184227 pubmed_primary_35961031 crossref_primary_10_1093_rheumatology_keac466 crossref_citationtrail_10_1093_rheumatology_keac466 oup_primary_10_1093_rheumatology_keac466 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2023-03-01 |
| PublicationDateYYYYMMDD | 2023-03-01 |
| PublicationDate_xml | – month: 03 year: 2023 text: 2023-03-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Rheumatology (Oxford, England) |
| PublicationTitleAlternate | Rheumatology (Oxford) |
| PublicationYear | 2023 |
| Publisher | Oxford University Press |
| Publisher_xml | – name: Oxford University Press |
| References | Pericleous (2023030119163482700_) 2016; 11 Palli (2023030119163482700_) 2019; 10 John (2023030119163482700_) 2018; 25 Svenungsson (2023030119163482700_) 2010; 69 Sáinz-Jaspeado (2023030119163482700_) 2021; 144 Oke (2023030119163482700_) 2019; 21 Parra-Izquierdo (2023030119163482700_) 2018; 38 Stewart (2023030119163482700_) 1997; 29 Selmi (2023030119163482700_) 2020; 300 Sarajlic (2023030119163482700_) 2021; 6 Thanassoulis (2023030119163482700_) 2013; 368 Kelchtermans (2023030119163482700_) 2016; 14 Svenungsson (2023030119163482700_) 2022; 291 Yu (2023030119163482700_) 2011; 337 Zuily (2023030119163482700_) 2011; 124 Plunde (2023030119163482700_) 2020; 13 Hasunuma (2023030119163482700_) 1997; 107 Corban (2023030119163482700_) 2017; 69 New (2023030119163482700_) 2011; 108 Vandevelde (2023030119163482700_) 2022; 20 Bäck (2023030119163482700_) 2021 Glaser (2023030119163482700_) 2021; 107 Bouchareb (2023030119163482700_) 2019; 40 Lindman (2023030119163482700_) 2016; 2 Yuan (2023030119163482700_) 2020; 63 Salina (2023030119163482700_) 2002; 108 Sellers (2023030119163482700_) 2021; 6 Ramesh (2023030119163482700_) 2011; 121 Remmers (2023030119163482700_) 2007; 357 Zheng (2023030119163482700_) 2019; 73 Otto (2023030119163482700_) 1994; 90 Shannon (2023030119163482700_) 2003; 13 Hollerbach (2023030119163482700_) 2019; 119 Otto (2023030119163482700_) 2014; 371 Capoulade (2023030119163482700_) 2015; 66 Folkersen (2023030119163482700_) 2010; 3 Grosso (2023030119163482700_) 2019; 170 Van der Heiden (2023030119163482700_) 2008; 196 Miyakis (2023030119163482700_) 2006; 4 Nyman (2023030119163482700_) 2014; 52 AbouAlaiwi (2023030119163482700_) 2009; 104 Mathieu (2023030119163482700_) 2019; 6 Schreiber (2023030119163482700_) 2018; 4 |
| References_xml | – volume: 69 start-page: 2317 year: 2017 ident: 2023030119163482700_ article-title: Antiphospholipid syndrome: role of vascular endothelial cells and implications for risk stratification and targeted therapeutics publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2017.02.058 – volume: 104 start-page: 860 year: 2009 ident: 2023030119163482700_ article-title: Ciliary polycystin-2 is a mechanosensitive calcium channel involved in nitric oxide signaling cascades publication-title: Circ Res doi: 10.1161/CIRCRESAHA.108.192765 – volume: 73 start-page: 2150 year: 2019 ident: 2023030119163482700_ article-title: Lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2019.01.070 – volume: 90 start-page: 844 year: 1994 ident: 2023030119163482700_ article-title: Characterization of the early lesion of ‘degenerative’ valvular aortic stenosis. Histological and immunohistochemical studies publication-title: Circulation doi: 10.1161/01.CIR.90.2.844 – volume: 107 start-page: 1167 year: 2021 ident: 2023030119163482700_ article-title: Relative survival after aortic valve surgery in patients with bicuspid aortic valves publication-title: Heart doi: 10.1136/heartjnl-2020-318733 – volume: 4 start-page: 17103 year: 2018 ident: 2023030119163482700_ article-title: Antiphospholipid syndrome publication-title: Nat Rev Dis Primers doi: 10.1038/nrdp.2017.103 – volume: 40 start-page: 1362 year: 2019 ident: 2023030119163482700_ article-title: Activated platelets promote an osteogenic programme and the progression of calcific aortic valve stenosis publication-title: Eur Heart J doi: 10.1093/eurheartj/ehy696 – volume: 4 start-page: 295 year: 2006 ident: 2023030119163482700_ article-title: International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) publication-title: J Thromb Haemost doi: 10.1111/j.1538-7836.2006.01753.x – volume: 121 start-page: 120 year: 2011 ident: 2023030119163482700_ article-title: Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via β2GPI and apoER2 publication-title: J Clin Invest doi: 10.1172/JCI39828 – volume: 29 start-page: 630 year: 1997 ident: 2023030119163482700_ article-title: Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study publication-title: J Am Coll Cardiol doi: 10.1016/S0735-1097(96)00563-3 – volume: 124 start-page: 215 year: 2011 ident: 2023030119163482700_ article-title: Increased risk for heart valve disease associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: meta-analysis of echocardiographic studies publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.111.028522 – volume: 196 start-page: 542 year: 2008 ident: 2023030119163482700_ article-title: Endothelial primary cilia in areas of disturbed flow are at the base of atherosclerosis publication-title: Atherosclerosis doi: 10.1016/j.atherosclerosis.2007.05.030 – volume: 119 start-page: 1147 year: 2019 ident: 2023030119163482700_ article-title: Platelet activation by antiphospholipid antibodies depends on epitope specificity and is prevented by mTOR inhibitors publication-title: Thromb Haemost doi: 10.1055/s-0039-1685453 – volume: 2 start-page: 16006 year: 2016 ident: 2023030119163482700_ article-title: Calcific aortic stenosis publication-title: Nat Rev Dis Primers doi: 10.1038/nrdp.2016.6 – volume: 6 start-page: 403 year: 2021 ident: 2023030119163482700_ article-title: Artificial intelligence models reveal sex-specific gene expression in aortic valve calcification publication-title: JACC Basic Transl Sci doi: 10.1016/j.jacbts.2021.02.005 – volume: 14 start-page: 1530 year: 2016 ident: 2023030119163482700_ article-title: IgG/IgM antiphospholipid antibodies present in the classification criteria for the antiphospholipid syndrome: a critical review of their association with thrombosis publication-title: J Thromb Haemost doi: 10.1111/jth.13379 – volume: 6 start-page: 1007 year: 2021 ident: 2023030119163482700_ article-title: Platelets: implications in aortic valve stenosis and bioprosthetic valve dysfunction from pathophysiology to clinical care publication-title: . JACC Basic Transl Sci doi: 10.1016/j.jacbts.2021.07.008 – volume: 300 start-page: 209 year: 2020 ident: 2023030119163482700_ article-title: Anti-phospholipid antibody prevalence and association with subclinical atherosclerosis and atherothrombosis in the general population publication-title: Int J Cardiol doi: 10.1016/j.ijcard.2019.10.042 – volume: 368 start-page: 503 year: 2013 ident: 2023030119163482700_ article-title: Genetic associations with valvular calcification and aortic stenosis publication-title: N Engl J Med doi: 10.1056/NEJMoa1109034 – volume: 13 start-page: e002710 year: 2020 ident: 2023030119163482700_ article-title: FADS1 (Fatty Acid Desaturase 1) genotype associates with aortic valve FADS mRNA expression, fatty acid content and calcification publication-title: Circ Genom Precis Med doi: 10.1161/CIRCGEN.119.002710 – volume: 291 start-page: 327 year: 2022 ident: 2023030119163482700_ article-title: Antiphospholipid antibodies in patients with myocardial infarction with and without obstructive coronary arteries publication-title: J Intern Med doi: 10.1111/joim.13409 – volume: 371 start-page: 744 year: 2014 ident: 2023030119163482700_ article-title: Aortic-valve stenosis–from patients at risk to severe valve obstruction publication-title: N Engl J Med doi: 10.1056/NEJMra1313875 – volume: 69 start-page: 834 year: 2010 ident: 2023030119163482700_ article-title: A STAT4 risk allele is associated with ischaemic cerebrovascular events and anti-phospholipid antibodies in systemic lupus erythematosus publication-title: Ann Rheum Dis doi: 10.1136/ard.2009.115535 – volume: 63 start-page: 116 year: 2020 ident: 2023030119163482700_ article-title: Association of genetic variants related to plasma fatty acids with type 2 diabetes mellitus and glycaemic traits: a Mendelian randomisation study publication-title: Diabetologia doi: 10.1007/s00125-019-05019-0 – volume: 337 start-page: 16 year: 2011 ident: 2023030119163482700_ article-title: Tumor necrosis factor-α accelerates the calcification of human aortic valve interstitial cells obtained from patients with calcific aortic valve stenosis via the BMP2-Dlx5 pathway publication-title: J Pharmacol Exp Ther doi: 10.1124/jpet.110.177915 – volume: 170 start-page: 277 year: 2019 ident: 2023030119163482700_ article-title: Antiphospholipid antibodies in patients with myocardial infarction publication-title: Ann Intern Med doi: 10.7326/M18-2130 – volume: 20 start-page: 508 year: 2022 ident: 2023030119163482700_ article-title: Semiquantitative interpretation of anticardiolipin and anti-β2-glycoprotein I antibodies measured with various analytical platforms: communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies publication-title: J Thromb Haemost doi: 10.1111/jth.15585 – volume: 52 start-page: 815 year: 2014 ident: 2023030119163482700_ article-title: The revised Lund-Malmö GFR estimating equation outperforms MDRD and CKD-EPI across GFR, age and BMI intervals in a large Swedish population publication-title: Clin Chem Lab Med doi: 10.1515/cclm-2013-0741 – volume: 10 start-page: 487 year: 2019 ident: 2023030119163482700_ article-title: Type I interferon signature in primary antiphospholipid syndrome: clinical and laboratory associations publication-title: Front Immunol doi: 10.3389/fimmu.2019.00487 – volume: 144 start-page: 1629 year: 2021 ident: 2023030119163482700_ article-title: Palmdelphin regulates nuclear resilience to mechanical stress in the endothelium publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.121.054182 – volume: 21 start-page: 107 year: 2019 ident: 2023030119163482700_ article-title: High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus publication-title: Arthritis Res Ther doi: 10.1186/s13075-019-1878-y – start-page: 2016 volume-title: Cardiovasc Res year: 2021 ident: 2023030119163482700_ – volume: 11 start-page: e0156407 year: 2016 ident: 2023030119163482700_ article-title: Measuring IgA Anti-β2-glycoprotein I and IgG/IgA anti-domain I antibodies adds value to current serological assays for the antiphospholipid syndrome publication-title: PLoS one doi: 10.1371/journal.pone.0156407 – volume: 108 start-page: 1381 year: 2011 ident: 2023030119163482700_ article-title: Molecular imaging insights into early inflammatory stages of arterial and aortic valve calcification publication-title: Circ Res doi: 10.1161/CIRCRESAHA.110.234146 – volume: 13 start-page: 2498 year: 2003 ident: 2023030119163482700_ article-title: Cytoscape: a software environment for integrated models of biomolecular interaction networks publication-title: Genome Res doi: 10.1101/gr.1239303 – volume: 25 start-page: 95 year: 2018 ident: 2023030119163482700_ article-title: IFIT1 exerts opposing regulatory effects on the inflammatory and interferon gene programs in LPS-activated human macrophages publication-title: Cell Rep doi: 10.1016/j.celrep.2018.09.002 – volume: 107 start-page: 569 year: 1997 ident: 2023030119163482700_ article-title: Involvement of beta 2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages publication-title: Clin Exp Immunol doi: 10.1046/j.1365-2249.1997.d01-948.x – volume: 66 start-page: 1236 year: 2015 ident: 2023030119163482700_ article-title: Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve stenosis publication-title: J Am Coll Cardiol doi: 10.1016/j.jacc.2015.07.020 – volume: 108 start-page: 97 year: 2002 ident: 2023030119163482700_ article-title: Cytoplasmic dynein as a facilitator of nuclear envelope breakdown publication-title: Cell doi: 10.1016/S0092-8674(01)00628-6 – volume: 3 start-page: 365 year: 2010 ident: 2023030119163482700_ article-title: Association of genetic risk variants with expression of proximal genes identifies novel susceptibility genes for cardiovascular disease publication-title: Circ Cardiovasc Genet doi: 10.1161/CIRCGENETICS.110.948935 – volume: 6 start-page: 18 year: 2019 ident: 2023030119163482700_ article-title: Autotaxin and lipoprotein metabolism in calcific aortic valve disease publication-title: Front Cardiovasc Med doi: 10.3389/fcvm.2019.00018 – volume: 38 start-page: 2148 year: 2018 ident: 2023030119163482700_ article-title: Calcification induced by type I interferon in human aortic valve interstitial cells is larger in males and blunted by a janus kinase inhibitor publication-title: Arterioscler Thromb Vasc Biol doi: 10.1161/ATVBAHA.118.311504 – volume: 357 start-page: 977 year: 2007 ident: 2023030119163482700_ article-title: STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus publication-title: New Engl J Med doi: 10.1056/NEJMoa073003 |
| SSID | ssj0005138 |
| Score | 2.4370852 |
| Snippet | Abstract
Objectives
The antiphospholipid syndrome is defined by antiphospholipid antibodies (aPL) together with arterial and/or venous thromboembolism and/or... The antiphospholipid syndrome is defined by antiphospholipid antibodies (aPL) together with arterial and/or venous thromboembolism and/or obstetric... |
| SourceID | unpaywall swepub pubmedcentral proquest pubmed crossref oup |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1187 |
| SubjectTerms | Aged Antibodies, Antiphospholipid Antiphospholipid Syndrome - complications Aortic Valve Aortic Valve Stenosis - etiology Clinical Science Female Humans Immunoglobulin G Lupus Erythematosus, Systemic - complications Male Pregnancy |
| Title | Antiphospholipid antibodies in patients with calcific aortic valve stenosis |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/35961031 https://www.proquest.com/docview/2702184227 https://pubmed.ncbi.nlm.nih.gov/PMC9977117 http://kipublications.ki.se/Default.aspx?queryparsed=id:150551168 https://academic.oup.com/rheumatology/advance-article-pdf/doi/10.1093/rheumatology/keac466/45600133/keac466.pdf |
| UnpaywallVersion | publishedVersion |
| Volume | 62 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1462-0332 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0005138 issn: 1462-0324 databaseCode: KQ8 dateStart: 19960101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1462-0332 dateEnd: 20241102 omitProxy: true ssIdentifier: ssj0005138 issn: 1462-0324 databaseCode: DIK dateStart: 19960101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1462-0332 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0005138 issn: 1462-0324 databaseCode: GX1 dateStart: 0 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwvV1Lj9MwEB7tdiUeB54LhMfKSAhxSbaxUyc5VohlBdqFw1Yqp8hObDVqlUSbBgS_gp_MuHZKA0IsFw6totQzSu0vmZl45huAFzTVMRoy7nOutR8lUe4nTFN_TEXIOc15IUy989k5P51F7-aT-R7UfS2McFnhQV_ScLlQHfpum3fMx25fvE8a85tC_6QgSNlw8BKfKRHnx9HGqDPWnwhQah8O-ASd9xEczM4_Tj_ZGiS8RGbb4NpjRvtiuz_oHhizQYHcjp_6e7qlIyW9Cde7qhFfv4jVaseondyG7_102FyWZdCtZZB_-4Up8j_O1x245RxkMrW67sKequ7BtTOXAnAf3k-rddks6hY_q7IpC4LYKGVtsiFJWRFHFNsS84aZIAI3SYdE1EYhwfvqsyKI7Kpuy_YQZidvLl6f-q4jhJ9HCV_7SsUiZkXKEWJShRqtq5ZaJAwXM0ZHb0LjsUCHUnIuDVG_6aUuBFNsrNBQa8YewKiqK_UISFLIIkfRVKYYEYcao2kuGRdRJDDgoNQD1i9tlju6dNO1Y5XZbXuW7U5e5ubKA38r1Vi6kL-Mf4ULd8Whz3toZfgIMPs6olJ112ampBADdUpjDx5aqG01MkS56eThQTwA4XaAoRcf_lKViw3NeIqhQRiizpcWrgMRd2qJRyqLJsYR9yDYwvlK_-jxvwo8gRsUfUybAvgURuvLTj1Dn3Atj2D_7TzE74sP8yN3T_8A6nBtjA |
| linkProvider | Unpaywall |
| linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwvV3di9QwEB_OPdDzwW_P-kUEEV_a2ybdtH1cDo9DucMHF86nkrQJW3Zpy7VV9K_wT3aySfe2ini--FAobWbYTX7tzDQzvwF4TVMdoyHjPuda-1ES5X7CNPWnVISc05wXwtQ7n53z00X0_mJ2sQf1UAsjXFZ4MJQ0XC5Vj77b5hvzkdsXH5LG_KbQVxQEKRsPXuE7JeL8KNoYdcaGCwFK3YB9PkPnfQL7i_OP88-2Bgl_IrNtcO05o0Ox3R90j4zZqEBux0_9Pd3SkZLehlt91YhvX8V6vWPUTu7Cj2E6bC7LKug7GeTff2GK_I_zdQ_uOAeZzK2u-7Cnqgdw88ylADyED_OqK5tl3eKxLpuyIIiNUtYmG5KUFXFEsS0xX5gJInCTdEhEbRQSfK6-KILIruq2bB_B4uTdp-NT33WE8PMo4Z2vVCxiVqQcISZVqNG6aqlFwnAxY3T0ZjSeCnQoJefSEPWbXupCMMWmCg21ZuwxTKq6Uk-AJIUschRNZYoRcagxmuaScRFFAgMOSj1gw9JmuaNLN1071pndtmfZ7uRlbq488LdSjaUL-cv4t7hw1xz6aoBWhq8As68jKlX3bWZKCjFQpzT24NBCbauRIcpNJw8P4hEItwMMvfj4TlUuNzTjKYYGYYg631i4jkTcpRWeqSyaGUfcg2AL52v9o6f_KvAMDij6mDYF8DlMustevUCfsJMv3XP8E9k7a38 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Antiphospholipid+antibodies+in+patients+with+calcific+aortic+valve+stenosis&rft.jtitle=Rheumatology+%28Oxford%2C+England%29&rft.au=Plunde%2C+Oscar&rft.au=Svenungsson%2C+Elisabet&rft.au=Ferrannini%2C+Giulia&rft.au=Franco-Cereceda%2C+Anders&rft.date=2023-03-01&rft.pub=Oxford+University+Press&rft.issn=1462-0324&rft.eissn=1462-0332&rft.volume=62&rft.issue=3&rft.spage=1187&rft.epage=1196&rft_id=info:doi/10.1093%2Frheumatology%2Fkeac466&rft_id=info%3Apmid%2F35961031&rft.externalDocID=PMC9977117 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1462-0324&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1462-0324&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1462-0324&client=summon |